Cosentyx half life?

Secukinumab (Cosentyx) – Half‑Life

- Average half‑life: ~27 days (≈3.9 weeks)
- Typical range reported in trials: 20 – 29 days, depending on dose, patient factors, and disease activity.

Because secukinumab is a human IgG1κ monoclonal antibody, it is cleared mainly by proteolytic degradation rather than by liver or kidney metabolism. Its long half‑life allows dosing intervals of 4 weeks (initially) and, after the first 4–8 doses, every 8 weeks in many treatment regimens.

Practical implication – After a single dose, it takes roughly 5–6 half‑lives (≈5–6 months) for the drug to fall below detectable levels. That’s why any adverse effects or therapeutic responses can persist for months after stopping therapy.

If you need more detailed pharmacokinetic data (e.g., variability by weight, gender, or concomitant medications), let me know!